Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: July 2026

Quick Answer

Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity. The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations. This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents.

Background:	Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies.
Objective:	To synthesize the preclinical and clinical evidence on all three drugs across cancer types, summarize the current mainstream oncology position, and outline safety considerations for patients and clinicians encountering this topic.
Methods:	Narrative synthesis of peer-reviewed in vitro, case-report, cohort, and trial literature, cross-referenced against ASCO's May 2026 Clinical Notice, the June 2026 journal Expression of Concern regarding the largest published observational cohort, and current safety case reports.
Results:	Preclinical data support plausible anticancer mechanisms for all three drugs. Human evidence is limited to a small randomized trial of mebendazole as a chemotherapy adjunct in colorectal cancer, an early-phase (Phase I/II) trial of ivermectin with checkpoint inhibitors in triple-negative breast cancer that has not yet reported efficacy results, scattered case reports, and one large observational cohort now under formal editorial scrutiny. Documented harms include hepatotoxicity, in at least one case from the combined ivermectin-fenbendazole regimen this topic is best known for online.
Conclusions:	The pharmacological rationale is real and merits continued, properly controlled trial investment. It does not yet support use outside a clinical trial, and the relevant professional body has said so directly. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.
Keywords:	ivermectin, fenbendazole, mebendazole, drug repurposing, ASCO clinical notice, CEBM evidence grading

Table of Contents

1. Why This Topic Keeps Coming Up
2. The Pharmacological Rationale
3. Evidence Hierarchy: What Kind of Proof Is This?
4. The Actual Human Clinical Trial Data
5. The 197-Patient Cohort and the Expression of Concern
6. ASCO's May 2026 Clinical Notice
7. The "Turbo Cancer" Claim: What the Evidence Shows
8. Documented Safety Signals
9. Reported Protocols in the Literature (Not Recommendations)
10. Who's Behind the Claims: A Note on Sources
11. Access, Cost, and Why Trials Are Slow
12. If You're Considering This: A Practical Framework
13. Using AI Assistants to Research This Topic
14. Frequently Asked Questions
15. Conclusion
16. References

1. Why This Topic Keeps Coming Up

Cancer remains a leading cause of morbidity and mortality worldwide, and aggressive, treatment-resistant tumors — triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, glioblastoma — continue to leave many patients with limited options even after real advances in targeted therapy and immunotherapy. Oncology drug spending exceeded $150 billion globally in 2022, and the pace of new-drug approval is slow relative to patient need. Against that backdrop, drug repurposing — finding new uses for existing, already-approved drugs — is a legitimate and active area of oncology research.

Ivermectin (a macrocyclic lactone antiparasitic) and the benzimidazole anthelmintics fenbendazole and mebendazole are among the most discussed repurposing candidates, following laboratory work dating back to a 2009 benzimidazole antitumor study and accelerating sharply after a widely shared 2019 account of fenbendazole use in lung cancer (the "Joe Tippens protocol") and, separately, ivermectin's COVID-era notoriety carrying over into cancer-focused online communities from 2021 onward.

This review exists because the gap between what circulates on social media and what has actually been demonstrated in controlled human trials is large — and because that gap has real, documented consequences, including published cases of liver injury (Section 8) and a major oncology body's formal recommendation against use outside a trial (Section 6). The underlying pharmacology is genuinely interesting and worth continued research investment. The goal of this update is to give patients, caregivers, and clinicians an accurate picture of exactly where the evidence stands in mid-2026 — not to dismiss the question, and not to overstate the answer.

2. The Pharmacological Rationale

Laboratory (in vitro and animal) studies support biologically plausible anticancer mechanisms for all three drugs. None of these findings has yet been confirmed to translate into a proven human treatment benefit at safe oral doses, but they explain why the hypothesis has drawn legitimate scientific interest.

Fenbendazole

A benzimidazole widely used in veterinary medicine, fenbendazole has shown anticancer effects in vitro by destabilizing microtubules, inducing G2/M cell-cycle arrest, and impairing glucose metabolism through inhibition of glucose transporters (GLUT1/4) and hexokinase, including in 5-fluorouracil-resistant colorectal cancer cell lines (Bai et al., 2009; Duan et al., 2013; Nguyen et al., 2024). Its poor water solubility and limited oral bioavailability remain a real pharmacokinetic barrier to achieving these laboratory concentrations in human blood.

Mebendazole

A structurally related benzimidazole with better bioavailability and decades of human use as an antiparasitic, mebendazole similarly disrupts microtubule polymerization and has shown activity across several preclinical cancer models — ovarian cancer, chronic myeloid leukemia, and glioblastoma — with some evidence of synergy alongside tyrosine kinase inhibitors (Chai et al., 2021; Guerini et al., 2019). Its ability to cross the blood-brain barrier has made it of particular interest for brain tumors, and it has the most human trial data of the three drugs discussed here (Section 4).

Ivermectin

Ivermectin acts through mechanisms distinct from the benzimidazoles: inhibition of oncogenic signaling pathways including STAT3, Wnt/β-catenin, and AKT/mTOR, induction of oxidative stress and apoptosis, and effects on cancer stem cell populations. Preclinical work has examined activity across more than 20 cancer types (Juarez et al., 2018; Tang et al., 2021), and a 2021 Nature Communications paper by Draganov et al. reported that ivermectin could convert immunologically "cold" breast tumors "hot" and synergize with checkpoint blockade in mouse models — the finding that underlies the human trial discussed in Section 4.

Important context, true across all three drugs: laboratory concentrations used in these studies frequently exceed what can be safely achieved in human blood at approved or even substantially escalated oral doses. A mechanism shown in a petri dish or a mouse does not automatically hold in a person taking the drug by mouth — that translational gap is exactly what clinical trials exist to test, and it has not yet been closed for any of these three drugs in oncology.

3. Evidence Hierarchy: What Kind of Proof Is This?

Not all "evidence" referenced on this topic carries the same weight. Using the CEBM (Centre for Evidence-Based Medicine) hierarchy:

CEBM Level	What It Means	Where It Applies Here
Level 1–2	Randomized controlled trials, systematic reviews of RCTs	One small placebo-controlled RCT of mebendazole in colorectal cancer (n=40). No completed RCT exists yet for ivermectin or fenbendazole in any cancer type.
Level 2–3 (in progress)	Early-phase trials, not yet reporting efficacy	Phase I/II ivermectin + checkpoint inhibitor trial in metastatic TNBC (safety data only so far); Phase II ICONIC trial beginning mid-2026.
Level 3	Cohort studies	One large self-reported observational cohort (197 patients) — see Section 5 for why this now carries a formal editorial caveat.
Level 4	Peer-reviewed, individually verified case reports	A small number of published case reports of both possible benefit and documented harm (Section 8).
Level 5	Expert opinion, mechanistic reasoning, in vitro/animal studies	The large majority of the mechanistic literature cited throughout this article and elsewhere on this topic.
Not clinical evidence	Self-reported, non-peer-reviewed anecdotes	The hundreds of social media "success story" compilations that circulate under this topic. Not independently verified; almost always confounded by concurrent conventional treatment; failures are rarely posted.

4. The Actual Human Clinical Trial Data

Ivermectin + Checkpoint Inhibitor in Metastatic TNBC (NCT05318469)

Led by Yuan Yuan and colleagues at Cedars-Sinai/City of Hope, this Phase I/II trial is testing oral ivermectin (30, 45, or 60 mg daily on days 1–3, 8–10, and 15–17 of each 21-day cycle) combined with the checkpoint inhibitor balstilimab or pembrolizumab in patients with metastatic TNBC who progressed on prior therapy. Preliminary safety data on the first nine enrolled patients were presented at the 2025 ASCO Annual Meeting; efficacy results have not yet been reported. A separate, larger randomized Phase II trial (ICONIC, NCT07487805) pairing different ivermectin doses with checkpoint inhibitors across 80 patients with solid tumors was expected to begin enrollment in July 2026, with results not anticipated before late 2027. As of this update, ASCO notes this is the only registered human cancer trial of ivermectin it is aware of.

Mebendazole + Bevacizumab + FOLFOX4 in Colorectal Cancer (Hegazy et al., 2022)

This is the single most rigorous piece of human evidence in this entire topic area, and it deserves to be reported precisely rather than folded in with anecdotal material. It was a prospective, randomized, double-blind, placebo-controlled trial of 40 metastatic colorectal cancer patients, published in Life Sciences. All patients received bevacizumab plus FOLFOX4 chemotherapy; 20 additionally received mebendazole 500 mg orally twice daily for 12 weeks, and 20 received placebo. At 12 weeks, the mebendazole group showed a 65% overall response rate versus 10% for placebo, and median progression-free survival of 9.25 months versus 3 months. These are striking numbers for a 40-patient, single-center trial — a legitimate reason for scientific optimism about mebendazole specifically as a chemotherapy adjunct, not a replacement — but they have not yet been independently replicated in a larger, multi-center trial, which is what would be required before this could influence treatment guidelines.

Case Report: Mebendazole With Dual Immunotherapy (Aydin et al., 2024)

Published in Frontiers in Oncology, this single case report described a heavily pretreated metastatic colorectal cancer patient who achieved a molecular complete response on a regimen combining nivolumab, ipilimumab, lenvatinib, and mebendazole (100 mg twice daily). As one case, it is hypothesis-generating, not proof of effect — but it is peer-reviewed, which places it in a different evidentiary category from an unverified social media account.

5. The 197-Patient Cohort and the Expression of Concern

In June 2026, Anticancer Research published Hulscher et al., "Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients," a prospective observational cohort of 197 patients prescribed a compounded ivermectin-mebendazole capsule (25 mg ivermectin / 250 mg mebendazole) off-label through a U.S. telemedicine platform. The paper reported that a large share of patients described tumor regression or no evidence of disease at six-month follow-up, and it was widely shared as the "largest human ivermectin cancer study ever conducted."

This needs full and current context. The study's authors are affiliated with The Wellness Company, the same telehealth company that markets a compounded ivermectin-mebendazole product — a direct financial interest in the result, which the paper itself needs to be read alongside. More importantly, in June 2026 the Editorial Board of Anticancer Research issued a formal Expression of Concern about the paper, following reports from the international medical community questioning the verifiability and statistical reliability of the underlying dataset and the adequacy of its ethical oversight. The Board noted the study was intended as hypothesis-generating groundwork for future randomized trials, not as evidence of efficacy. Independent commentary (e.g., Dr. Jill Carnahan's review) has also pointed out the study's design limitations directly: outcomes were entirely self-reported, there was no control group, roughly a third of participants were on concurrent chemotherapy, and the study cannot establish that the drugs — rather than standard treatment, natural disease variation, or reporting bias — caused any reported improvement.

The pharmacological question this cohort was trying to answer is a fair one. But as of this update, the paper carries a live editorial caveat from its own publishing journal, and should not be cited as settled evidence of efficacy or safety.

6. ASCO's May 2026 Clinical Notice

In May 2026, the American Society of Clinical Oncology — the largest professional body of oncologists in the United States — published a formal Clinical Notice addressing ivermectin and fenbendazole in cancer directly. Its core points:

• There is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy.
• ASCO "strongly cautions" that neither drug should be used to treat cancer, or as an adjunct to established cancer therapy, outside the regulatory safeguards of a well-designed clinical trial.
• The combination of unproven benefit and documented potential for toxicity and drug interaction "presents an unacceptable risk to patients."
• Fenbendazole holds no FDA or EMA approval for any human indication; ivermectin is FDA-approved only for specific parasitic infections, at doses well below those described in online cancer regimens.
• ASCO explicitly frames the social-media spread of these regimens as a patient-safety issue and urges oncologists to proactively ask patients about outside drug and supplement use rather than wait for voluntary disclosure.

This is the current mainstream clinical position, and it should sit alongside — not replace — the preclinical rationale discussed in Section 2. Readers are entitled to both halves of the picture; this article aims to give them both.

7. The "Turbo Cancer" Claim: What the Evidence Shows

Much of the urgency behind self-administered ivermectin/fenbendazole regimens stems from the claim that COVID-19 mRNA vaccination is causing "turbo cancer" — unusually aggressive, fast-progressing malignancies. This claim deserves a direct, current answer rather than a passing mention, because it materially changes how a reader should weigh the "act now, ask questions later" framing that sometimes accompanies it.

As of this update, the claim is not supported by the evidence. The National Cancer Institute, the American Cancer Society, and multiple independent fact-checking organizations have found no population-level data showing increased cancer incidence or accelerated tumor growth following mRNA vaccination, and no plausible biological mechanism: mRNA vaccines do not enter the cell nucleus and cannot alter a person's DNA. A high-profile 2025 claim that former President Joe Biden's aggressive prostate cancer was vaccine-induced "turbo cancer" was independently rated false by fact-checkers, who noted that a Gleason 9 prostate cancer is simply consistent with aggressive disease at diagnosis, a well-recognized clinical pattern that predates mRNA vaccines by decades. Reported instances of rapid post-vaccination cancer progression are more plausibly explained by the unmasking of a pre-existing, previously undiagnosed cancer, or by known biological variability in a genetically susceptible individual — not by a new, vaccine-caused disease entity.

This article does not take a position on COVID-19 vaccine policy, which is a separate and legitimately contested public discussion. But "turbo cancer" specifically, as a claimed cancer-causing mechanism, is a distinct empirical question, and on that narrow question the current evidence does not support it. Readers making treatment decisions under the belief that they are managing a vaccine-caused cancer variant should know that mainstream oncology and cancer-surveillance bodies do not recognize it as a real diagnostic category.

8. Documented Safety Signals

Hepatotoxicity Is Not Theoretical

Multiple published case reports now document drug-induced liver injury from unsupervised use of these agents:

• A 2021 Case Reports in Oncology case documented severe liver injury in an 80-year-old lung cancer patient after one month of self-administered fenbendazole taken on the basis of social media claims.
• A 2026 Cureus case report (Powderly et al.) described a patient who developed severe hepatocellular injury — ALT over 1,700 U/L, bilirubin near 13 mg/dL — after combining ivermectin and fenbendazole based on advice from an online cancer support group. A formal causality assessment (RUCAM score of 9) found the drug combination "highly probable" as the cause; the authors noted the combined regimen may impose greater hepatotoxic stress than either drug alone.
• A January 2026 World Journal of Clinical Cases report detailed the difficulty of distinguishing fenbendazole-induced liver injury from immunotherapy-related hepatitis in a patient on concurrent checkpoint inhibitor therapy — a diagnostic confusion that can delay recognition of either problem.

In several of these cases, liver function recovered after the drug was stopped, but recovery took weeks to months, and the injury was severe enough to require hospitalization and workup in some patients.

Veterinary Formulations Are Not Human Formulations

Fenbendazole is manufactured and regulated as an animal dewormer (marketed for dogs and livestock under names including Panacur and Safe-Guard). These products are not manufactured, tested, or dosed to human pharmaceutical standards, and their purity and excipients are not controlled for human oral consumption.

Known Drug Interactions

Mebendazole and metronidazole should not be combined at higher doses (mebendazole >500 mg with metronidazole >500 mg): the combination has been associated with rare but fatal Stevens-Johnson syndrome and toxic epidermal necrolysis (Chen et al., 2003). Ivermectin and the benzimidazoles are also metabolized through hepatic cytochrome P450 pathways that overlap with several standard chemotherapy agents, creating a real potential for altered drug clearance that is not yet well characterized in humans — precisely the concern ASCO names explicitly.

Never conceal supplement or drug use from your oncology team. Disclosure allows baseline and follow-up liver monitoring and lets your treating physician correctly interpret labs, scans, and any unexpected side effects.

9. Reported Protocols in the Literature (Not Recommendations)

Several named regimens are widely discussed online. They are described here as a matter of record — what has been reported and by whom — not as guidance to follow. None of the doses below have been established as safe or effective by a completed controlled trial, and ASCO's Clinical Notice (Section 6) applies to all of them.

• The Joe Tippens protocol: Popularized after a 2016 non-small-cell lung cancer patient reported using fenbendazole alongside curcumin and other supplements; he has since reported remaining cancer-free. It is a single, widely publicized personal account, not a studied protocol.
• Trial and case-report doses actually used in the literature: the Hegazy RCT used mebendazole 500 mg twice daily; the ongoing Cedars-Sinai trial uses ivermectin 30–60 mg daily on an intermittent schedule under clinical supervision with lab monitoring; the Hulscher cohort's compounded capsule combined 25 mg ivermectin with 250 mg mebendazole. These figures are reported here as data about what has been studied, not as a regimen to replicate at home.
• High-dose regimens circulated on social media — commonly citing figures such as fenbendazole 444–888 mg/day, mebendazole up to 4 g/day, or ivermectin dosed by body weight — originate largely from individual online advocates rather than a completed clinical trial, and several of the safety cases in Section 8 involved patients following exactly this kind of unsupervised, socially sourced dosing.

If you are drawn to any of these regimens, the responsible next step is a conversation with your oncology team about clinical trial enrollment (Section 4) or, at minimum, disclosure and monitoring — not independent sourcing and dosing.

10. Who's Behind the Claims: A Note on Sources

A large share of the personal dosing recommendations attached to this topic circulate under the name of Dr. William Makis, a Canadian radiologist whose commentary has been widely shared and republished across integrative-oncology sites. Readers evaluating how much weight to give his specific clinical recommendations deserve accurate, current context: Makis's permit to practise medicine in Alberta has been inactive since 2019, and in March 2026 the Alberta Court of King's Bench granted the College of Physicians & Surgeons of Alberta a permanent injunction restricting him from representing himself as licensed to practise medicine, from offering health services or cancer-treatment advice to the public, and from using the title "doctor" or "oncologist" in connection with providing a health service. In June 2026, the Alberta Court of Appeal rejected his bid to overturn that decision. The court found his activity — reviewing patient records, analyzing test results, and issuing specific treatment protocols — constituted the unauthorized practice of medicine; the court also noted its ruling concerned licensing, not a judgment on ivermectin or fenbendazole themselves. This is a matter of public record, not an editorial opinion, and it is directly relevant to how much evidentiary weight his personal protocol recommendations should carry relative to the peer-reviewed literature discussed above.

11. Access, Cost, and Why Trials Are Slow

All three drugs are off-patent and inexpensive, which is a genuine, well-documented structural barrier to trial funding: pharmaceutical sponsors generally fund large, expensive Phase III trials for drugs they can patent and price to recoup that investment, and off-patent generics rarely attract that kind of commercial sponsorship. That is a real and often-cited problem in oncology drug-repurposing research generally — for these drugs and many others — and it is a fair criticism of how oncology trials get funded. It is a separate claim from "these drugs are proven and being suppressed," which the evidence in Sections 4–6 does not support. Trials for both drugs do exist and are proceeding (Section 4); they are simply smaller and slower than a large pharmaceutical-sponsored program would be.

12. If You're Considering This: A Practical Framework

Step	Why It Matters
Tell your oncologist you're considering it — before you start	Allows baseline liver/kidney monitoring and a real review of interactions with your specific treatment regimen.
Ask about clinical trial enrollment	The ICONIC trial and the ivermectin/checkpoint-inhibitor TNBC trial offer a path to receiving ivermectin within a monitored, regulated setting.
Never substitute for guideline chemotherapy, surgery, radiation, or immunotherapy	No trial has tested these agents as monotherapy replacements for standard treatment; the one positive RCT used mebendazole strictly as an add-on to full-dose chemotherapy.
Never source from veterinary/animal-medicine channels	Animal formulations are not manufactured or dosed to human pharmaceutical standards.
Request liver-function monitoring if you and your physician proceed	Multiple published cases of serious drug-induced liver injury exist from unsupervised use, including the combined ivermectin-fenbendazole regimen.

13. Using AI Assistants to Research This Topic

If you're using an AI assistant such as Claude, ChatGPT, Gemini, or Perplexity to dig further into this subject, a few prompts get better results than a general question:

• Ask for the current status of a specific trial by its NCT number (e.g., "what is the current status of NCT05318469?") rather than a general "does ivermectin cure cancer" question — trial status changes and a specific identifier gets you a verifiable answer.
• Ask the assistant to distinguish evidence tiers explicitly — "is this a randomized trial, a case report, or a self-reported survey?" — since headlines and social posts routinely blur this distinction.
• Ask whether a cited study has any published editorial notices (corrections, expressions of concern, retractions) attached to it, since these can post-date the original coverage, as happened with the cohort discussed in Section 5.
• Cross-check any named clinician's current licensing status if a recommendation is being attributed to "Dr." so-and-so, particularly for claims made outside a clinical trial setting.

14. Frequently Asked Questions

Do ivermectin, fenbendazole, or mebendazole cure cancer?
No. No completed randomized controlled trial has shown that any of the three cures cancer in humans. Laboratory and animal studies show plausible anticancer mechanisms, and a small trial found mebendazole improved outcomes as an add-on to standard chemotherapy in colorectal cancer, but this is not the same as a proven standalone cure.

What does ASCO say about using these drugs for cancer?
In a May 2026 Clinical Notice, ASCO stated there is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy, and strongly cautioned against using either outside a registered clinical trial.

Is the 197-patient ivermectin/mebendazole study reliable?
It should be read with caution. The paper (Hulscher et al., 2026) reported favorable self-reported outcomes, but its authors are affiliated with the company that sells the product studied, and the publishing journal issued a formal Expression of Concern in June 2026 over the dataset's verifiability and reliability.

Is "turbo cancer" real?
Major cancer authorities, including the National Cancer Institute and American Cancer Society, along with independent fact-checkers, have found no evidence that mRNA COVID-19 vaccines cause unusually aggressive cancers, and no biological mechanism by which this could occur.

What are the real risks of taking these drugs without medical supervision?
Published case reports document serious, sometimes hospitalization-requiring liver injury, including from the combined ivermectin-and-fenbendazole regimen specifically. There is also a documented drug interaction risk between mebendazole and metronidazole, and potential interactions with standard chemotherapy metabolism.

Are there any legitimate human trials of these drugs in cancer?
Yes. A Phase I/II trial of ivermectin with checkpoint inhibitors is ongoing in metastatic triple-negative breast cancer, with a larger Phase II trial (ICONIC) beginning in 2026. A small, well-designed randomized trial of mebendazole as a chemotherapy adjunct in colorectal cancer has already been published.

15. Conclusion

The honest version of this topic is less dramatic than the version that circulates on social media, but it is more useful to a patient making decisions under real pressure. The pharmacological rationale for repurposing ivermectin, fenbendazole, and mebendazole in oncology is genuine and worth continued, properly designed trial investment — mebendazole's colorectal cancer data in particular. What the evidence does not yet show is that any of the three treats cancer as a standalone therapy, and the field's own professional body has said so directly, in the same month a widely cited real-world study of the combination came under formal editorial scrutiny. Patients deserve to hear the legitimate research question and, with equal clarity, that the current evidence does not support replacing standard treatment, that unsupervised self-dosing carries documented and sometimes serious risk, and that full transparency with an oncology team is a safety requirement rather than an optional courtesy.

Medical Disclaimer

This article is for educational purposes only and is not medical advice, and it is not a treatment protocol. Fenbendazole is not approved for human use under any indication. Ivermectin is FDA-approved only for specific parasitic infections, at doses well below those discussed in online cancer regimens. ASCO recommends against using either drug to treat cancer, or alongside cancer treatment, outside of a registered clinical trial. Do not start, stop, or combine any medication or supplement without your treating oncologist's direct knowledge and supervision.

Affiliate Disclosure: Some links on this page are affiliate links, including The Wellness Company (referral program) and Amazon Associates. If you purchase through these links, this site may earn a commission at no additional cost to you. This disclosure applies regardless of what the linked product's own sponsored or affiliated research does or does not show, including the study discussed in Section 5.

References

1. Bai RY, Staedtke V, Rudin CM, Bunz F, Riggins GJ. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro Oncol. 2015. (Foundational benzimidazole-cancer work following Bai et al. 2009.)
2. Nguyen L, et al. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Res. 2024;44(9):3725.
3. Chai JY, et al. Mebendazole as a repurposed drug: mechanisms and dosing in oncology. 2021.
4. Draganov D, et al. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer. 2021;7:22.
5. Yuan Y, Bitar JS, Walker M, et al. A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer. J Clin Oncol. 2025;43:16s(suppl; abstr e13146).
6. ClinicalTrials.gov. Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC). NCT07487805.
7. Hegazy SK, El-Azab GA, Zakaria F, Mostafa MF, El-Ghoneimy RA. Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. Life Sci. 2022;299:120536.
8. Aydin B, et al. Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and mebendazole. Front Oncol. 2024.
9. Hulscher N, Victory K, Thorp JA, et al. Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Res. 2026;46(6):3243-3255.
10. Editorial Board. Expression of Concern: Hulscher et al., Anticancer Res 2026;46(6):3243-3255. Anticancer Res. 2026;46(6):e3243.
11. American Society of Clinical Oncology. ASCO Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials. May 2026.
12. Yamaguchi T, Shimizu J, Oya Y, Horio Y, Hida T. Drug-induced liver injury in a patient with non-small cell lung cancer after the self-administration of fenbendazole based on social media information. Case Rep Oncol. 2021;14:886-891.
13. Powderly J, et al. Severe hepatotoxicity following combined ivermectin and fenbendazole self-administration in a cancer patient: a case report. Cureus. 2026;18(5):e108896.
14. Krishnan A, Lucas K, Maas L, Woreta TA. Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis. World J Clin Cases. 2026;14(2):116700.
15. Chen CY, et al. Stevens-Johnson syndrome associated with mebendazole and metronidazole co-administration. 2003. PMID: 12604501.
16. College of Physicians & Surgeons of Alberta. Statement: William (Viliam) Makis not licensed to practise medicine in Alberta. Updated March 2026.
17. College of Physicians and Surgeons of Alberta v Makis, 2026 ABCA 198 (CanLII).
18. PolitiFact. No, Joe Biden didn't get "turbo cancer" from COVID-19 vaccines. May 2025.

RELATED: 

Best Alternative Cancer Treatments (2026)

Potential Role of Fenbendazole and Ivermectin in the Treatment of Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2025)

Mel Gibson had 3 Friends cure their Stage Four Cancer with Fenbendazole and Ivermectin

Turbo Cancer Debunked

Fenbendazole vs Mebendazole for cancer

Fenbendazole vs Ivermectin for cancer

Top 10 cancer fighting supplements

Joe Tippens Protocol Fenbendazole

Read More: This article is part of the Integrative Oncology series.

Like and Follow us for more updates on Substack and X/Twitter.

The Wellness Company's Ivermectin and Mebendazole

Ivermectin and mebendazole, both approved for human use, are now available in the U.S.

Researched and approved by Dr. Peter McCullough.

• Prescribed by licensed medical professionals
• Compounded and dispensed by a licensed US-based pharmacy
• Approved for human use

Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.